Alecensa
Phase III ALINA study shows Alecensa’s superior disease-free survival benefit in early-stage lung cancer patients
Anika Sharma
ESMO 2023: LBA2 About 4-5% of NSCLC cases are identified with ALK rearrangements. In 2015, Alecensa (alectinib) received accelerated approval ...
Roche’s Alecensa beats chemo in early-stage lung cancer, following Tecentriq’s lead
Anika Sharma
With Tecentriq approval, Roche is once again celebrating success, this time in a promising early-stage lung cancer trial starring Alecensa, ...
